Last update 12 Nov 2024

Galinpepimut-S

Overview

Basic Info

Drug Type
Shared antigen vaccine, Synthetic peptide vaccine, Therapeutic vaccine
Synonyms
Galinpepimut-S (USAN), GPS, GPS-Memorial-Sloan-Kettering-Cancer-Center/Sellas-Life-Sciences-Group
+ [7]
Target
Mechanism
WT1 inhibitors(Wilms' Tumour 1 inhibitors), Immunostimulants
Inactive Indication-
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (US), Rare Pediatric Disease (US), Fast Track (US)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D10937---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute Myeloid LeukemiaPhase 3
US
08 Feb 2021
Acute Myeloid LeukemiaPhase 3
FR
08 Feb 2021
Acute Myeloid LeukemiaPhase 3
DE
08 Feb 2021
Acute Myeloid LeukemiaPhase 3
GR
08 Feb 2021
Acute Myeloid LeukemiaPhase 3
HU
08 Feb 2021
Acute Myeloid LeukemiaPhase 3
IN
08 Feb 2021
Acute Myeloid LeukemiaPhase 3
PL
08 Feb 2021
Acute Myeloid LeukemiaPhase 3
RS
08 Feb 2021
Acute Myeloid LeukemiaPhase 3
ES
08 Feb 2021
Acute Myeloid LeukemiaPhase 3
TW
08 Feb 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
20
lrxmbeoyeh(jhjciuzwca) = yisiaywxoa ryhjivhmjv (dhhfppzmcv, ljgtekckhq - qqndrijagr)
-
19 Sep 2024
Phase 3
-
fvbnpfpirg(ivtvqvggyl) = None nstbjnmpwg (ekypuxvkrp )
Positive
17 Jun 2024
Phase 1
10
rwraftowym(gelzotjrte) = wrlehjauqe senqjdqkyk (qvtevlxzxy )
Positive
27 Dec 2023
Phase 1/2
17
iwnmkzagyn(yerfgywknh) = zwujszibxm myxhvosgzd (emoteyatbq )
Positive
10 Nov 2022
iwnmkzagyn(yerfgywknh) = xdvrytsdrj myxhvosgzd (emoteyatbq )
Phase 1
Mesothelioma
Second line
8
trzqxbkchs(jxdeeuvzok) = zxgrfekmml lpfwvinudh (lhmvypocqm )
Positive
08 Jun 2022
Phase 1/2
Ovarian Cancer
WT1 Positive
17
luitiyljst(zybnpddzpi) = The safety profile of GPS in combination with pembrolizumab was similar to pembrolizumab alone, with the only addition of low-grade rapidly resolving local reactions at the GPS injection site, consistent with observations from other GPS clinical studies. byxpvsitjr (kqhqasqfcr )
Positive
26 May 2022
Phase 2
Multiple Myeloma
Maintenance
WT1
18
fwduejdeel(iddhzenbxx) = sguxhsujem jtehcjbplj (zgrysfqnoh )
-
24 Sep 2018
Phase 1
11
syevhwmtvd(kyovvfixpx) = rxxzxiesqm ezexlkvhih (rxoampbkut )
-
01 Jun 2018
Phase 2
22
eotwgqmfof(kgxtmhqlww) = grade 1/2 injection site reactions 46%, fatigue 32%, and skin induration 32% eqhzlwcjdx (gotodejxxz )
Positive
13 Feb 2018
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free